Pyrogen testing market seen reaching $5.21 billion by 2035

The global pyrogen testing market is projected to grow from $1.86 billion in 2026 to $5.21 billion by 2035, according to Market Research Future. Regulatory shifts toward animal-free testing, rising biologics output and faster automation are expected to drive demand across pharma, biotech and medical device manufacturers.

Why it matters: - Pyrogen testing is becoming a larger compliance cost center as regulators push manufacturers away from animal-based methods and toward validated alternatives. - The shift affects injectable drugs, biologics, biosimilars and some medical devices, where pyrogen clearance is required before release. - Faster, lower-sample testing can shorten batch-release timelines and reduce manufacturing delays.

What happened: - Market Research Future projects the global pyrogen testing market will rise from $1.86 billion in 2026 to $5.21 billion by 2035. - The forecast implies a 12.10% compound annual growth rate from 2026 to 2035. - The market was estimated at $1.66 billion in 2025. - The report ties growth to pharmacopeial changes, biologics pipeline growth and automation in endotoxin detection. - The report says the data reflect market conditions as of June 30, 2026.

The details: - The United States Pharmacopeia accepted recombinant Factor C, or rFC, assays under Chapter <85>. - The European Pharmacopoeia is phasing out the rabbit pyrogen test, with full removal targeted by 2026. - A joint EDQM and EPAA symposium in Brussels in February 2026 addressed the rabbit pyrogen test phase-out and recombinant Cascade Reagents. - The report says 78 innovative biologics were approved by international regulatory bodies in 2024, up from 64 in 2022. - The global biosimilar pipeline exceeded 1,200 molecules in active development in 2024. - More than 60% of novel biologic NDAs filed with the FDA between 2022 and 2024 came from U.S.-based facilities. - Automated microfluidic systems have cut sample sizes by up to 80% and reduced endotoxin turnaround from 18-24 hours to less than four hours. - Biopharma companies invested an estimated $320 million in MAT and rFC validation programs between 2022 and 2024. - Portable cartridge-based analyzers are said to cost about 40% less than benchtop systems. - Cloud-connected endotoxin analyzers can feed subscription analytics models. - Kits and reagents held about 60.6% of revenue in 2025. - Instruments are projected to grow at a 14.56% CAGR from 2026 to 2035. - Animal-based tests held about 67.4% of revenue in 2025. - Recombinant and cell-based tests are projected to grow at a 15.80% CAGR. - LAL tests held about 56.9% of revenue in 2025. - Monocyte Activation Test, or MAT, is projected to grow at a 16.82% CAGR. - Pharmaceutical and biotechnology companies held about 63.4% of end-user revenue in 2025. - Medical device manufacturers are projected to grow at a 14.38% CAGR. - North America held about 41.9% of the market in 2025. - Europe held about 27.5% of the market and was valued at $0.46 billion in 2025. - Asia-Pacific is projected to grow at a 14.58% CAGR. - The Middle East and Africa held about 4.9% of the market in 2025.

Between the lines: - Regulatory convergence in the U.S. and Europe is creating a structural pull toward recombinant and cell-based testing, not just a cyclical spending bump. - The largest near-term opportunity appears to be in companies that can bridge legacy LAL workflows with newer rFC and MAT platforms. - Market concentration remains moderate, with the top five companies holding an estimated 52% to 58% combined share. - Charles River Laboratories, Lonza Group, Associates of Cape Cod, Merck KGaA and bioMérieux are highlighted as key competitors. - The report expects AI-assisted quality control to gain traction by 2030, with about 35% of high-throughput QC labs using AI-assisted endotoxin trend analysis.

What's next: - EU manufacturers will need to complete validation of alternative methods ahead of the rabbit test phase-out deadline. - Companies that secure early regulatory acceptance for rFC or MAT platforms may capture share as compliance deadlines approach. - High-throughput labs are likely to keep investing in microfluidic and automation-ready systems. - The report expects AI-integrated QC workflows to reduce per-lot compliance costs by 20% to 25% by 2030.

The bottom line: - Pyrogen testing is shifting from a legacy QC task to a fast-growing, regulation-driven market built around animal-free methods, automation and biologics production growth.